Have a feature idea you'd love to see implemented?
Let us know!
ATNM Actinium Pharmaceuticals Inc
Price (delayed)
$1.17
Market cap
$36.5M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.39
Enterprise value
-$40.45M
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Actinium's lead application
Highlights
The EPS has grown by 28% YoY and by 8% from the previous quarter
The debt has decreased by 23% YoY and by 7% from the previous quarter
The equity has declined by 13% since the previous quarter and by 12% year-on-year
Key stats
What are the main financial stats of ATNM
Market
Valuations
Earnings
Shares outstanding
31.2M
Market cap
$36.5M
Enterprise value
-$40.45M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.95
Price to sales (P/S)
448.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-499.38
Revenue
$81,000
Gross profit
$81,000
Net income
-$40.92M
EBIT
-$40.92M
EBITDA
-$40.11M
Free cash flow
-$34.82M
Per share
Balance sheet
Liquidity
EPS
-$1.39
EPS diluted
-$1.39
Free cash flow per share
-$1.12
Book value per share
$1.23
Revenue per share
$0
TBVPS
$2.64
Total assets
$82.11M
Total liabilities
$43.91M
Debt
$1.71M
Equity
$38.21M
Working capital
$71.77M
Debt to equity
0.04
Current ratio
10.25
Quick ratio
10.14
Net debt/EBITDA
1.92
Margins
Efficiency
Dividend
EBITDA margin
-49,517.3%
Gross margin
100%
Net margin
-50,512.3%
Operating margin
-55,504.9%
Return on assets
-47.9%
Return on equity
-100.9%
Return on invested capital
N/A
Return on capital employed
-55%
Return on sales
-50,512.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ATNM stock price
How has the Actinium Pharmaceuticals stock price performed over time
Intraday
-2.5%
1 week
-5.65%
1 month
-18.75%
1 year
-76.97%
YTD
-76.97%
QTD
-37.77%
Financial performance
How have Actinium Pharmaceuticals's revenue and profit performed over time
Revenue
$81,000
Gross profit
$81,000
Operating income
-$44.96M
Net income
-$40.92M
Gross margin
100%
Net margin
-50,512.3%
ATNM's net income is up by 18% year-on-year and by 4% since the previous quarter
The operating income has increased by 15% year-on-year and by 3.7% since the previous quarter
The net margin has increased by 4% from the previous quarter
Actinium Pharmaceuticals's operating margin has increased by 3.7% from the previous quarter
Growth
What is Actinium Pharmaceuticals's growth rate over time
Valuation
What is Actinium Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.95
P/S
448.81
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-499.38
The EPS has grown by 28% YoY and by 8% from the previous quarter
The price to book (P/B) is 76% lower than the last 4 quarters average of 3.9 and 73% lower than the 5-year quarterly average of 3.5
The equity has declined by 13% since the previous quarter and by 12% year-on-year
ATNM's price to sales (P/S) is 77% less than its last 4 quarters average of 1958.9
Efficiency
How efficient is Actinium Pharmaceuticals business performance
ATNM's return on equity is down by 11% year-on-year
The ROS has grown by 4% from the previous quarter
The company's return on assets rose by 3.4% YoY and by 2% QoQ
Dividends
What is ATNM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ATNM.
Financial health
How did Actinium Pharmaceuticals financials performed over time
Actinium Pharmaceuticals's total assets is 87% more than its total liabilities
The quick ratio has increased by 15% from the previous quarter and by 6% YoY
Actinium Pharmaceuticals's current ratio has increased by 15% QoQ and by 3.9% YoY
The debt is 96% less than the equity
The debt has decreased by 23% YoY and by 7% from the previous quarter
The company's debt to equity fell by 20% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.